Co-Diagnostics Expands South Asian Distribution Through CoSara Joint Venture

Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka. This expansion significantly increases the company's addressable market to an estimated $13.0 billion, representing a substantial growth opportunity for the molecular diagnostics company. The move supports planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals, as the company builds regional distribution channels and positions for broader deployment of its molecular diagnostics solutions.

The expansion comes as Co-Diagnostics continues to develop its proprietary technology platform for molecular diagnostics applications. The company's technologies are utilized for tests designed using the detection and analysis of nucleic acid molecules (DNA or RNA), with applications extending beyond infectious disease diagnostics. This South Asian expansion represents a strategic move to increase market penetration in a region with significant healthcare needs and growing demand for advanced diagnostic solutions. The company's approach involves leveraging its joint venture structure to navigate regional markets while maintaining focus on its core technology development.

CoSara Diagnostics' expanded territory now covers key South Asian markets with combined populations exceeding 400 million people, creating substantial opportunities for growth in molecular diagnostics adoption. The planned commercialization of the point-of-care platform aligns with global trends toward decentralized testing and rapid diagnostic solutions. This expansion strategy demonstrates the company's commitment to increasing accessibility to molecular diagnostics in emerging markets while building sustainable distribution networks. The success of this initiative will depend on obtaining necessary regulatory approvals across the newly added territories, which represents both a challenge and opportunity for market entry.

The broader context of this announcement relates to increasing global demand for molecular diagnostics, particularly in regions with developing healthcare infrastructure. Co-Diagnostics' technology platform, including its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale), represents the company's approach to addressing diverse diagnostic needs. The South Asian expansion through the CoSara joint venture provides a framework for scaling operations while adapting to regional market conditions. This strategic move positions the company to capture market share in a rapidly growing diagnostics sector while contributing to improved healthcare access in the region through advanced testing solutions.